Another real-world study that supports the data from the phase III study described above is a Canadian multicenter study of 50 patients who received CPX-351 for t-AML and AML-MRC, 10 of whom had mutations in FLT3 (eight ITD and two TKD). The gene discussed is FLT3; the disease is acute myeloid leukemia.